LGND Ligand Pharmaceuticals Incorporated

$199.23

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Updated On 11/21/2025

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.

Website: https://www.ligand.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
886163
Address
11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA, CA, US
Valuation
Market Cap
$2.02B
P/E Ratio
nan
PEG Ratio
1.53
Price to Book
2.43
Performance
EPS
$-0.22
Dividend Yield
Profit Margin
-2.41%
ROE
-0.53%
Technicals
50D MA
$110.51
200D MA
$108.61
52W High
$129.90
52W Low
$67.72
Fundamentals
Shares Outstanding
19M
Target Price
$143.50
Beta
0.97

LGND EPS Estimates vs Actual

Estimated
Actual

LGND News & Sentiment

Nov 17, 2025 • Motley Fool SOMEWHAT-BULLISH
This Fund Sold $9 Million of Ligand Stock After an 84% Rally - What Investors Should Know
A high-conviction fund just trimmed one of its biggest winners-here's what long-term investors should make of the move.
Nov 10, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
NEW HOPE, Pa., Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- Orchestra BioMed Holdings, Inc. ( Nasdaq: OBIO, "Orchestra BioMed" or the "Company" ) , a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the ...
Nov 07, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Pelthos Therapeutics Acquires Xepi® ( ozenoxacin ) Cream, 1% and Announces $18 Million Private Convertible Notes Financing
DURHAM, N.C., Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Pelthos Therapeutics Inc. ( NYSE American: PTHS ) , a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ( "Pelthos" ) , today announced it has acquired the U.S. commercialization rights ...
Nov 07, 2025 • Benzinga SOMEWHAT-BULLISH
Pelthos Therapeutics Acquires Xepi® ( ozenoxacin ) Cream, 1% and Announces $18 Million Private Convertible Notes Financing - Ligand Pharmaceuticals ( NASDAQ:LGND ) , Pelthos Therapeutics ( AMEX:PTHS )
Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™ Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in antibiotic-resistant skin infections caused by staph and strep infections, most commonly affecting ...
Nov 07, 2025 • Benzinga NEUTRAL
EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch - Pelthos Therapeutics ( AMEX:PTHS )
Pelthos Therapeutics Inc. ( NYSE:PTHS ) on Friday acquired the U.S. commercialization rights to Xepi ( ozenoxacin ) Cream, 1%, from Biofrontera Inc. ( NASDAQ:BFRI ) and Ferrer Internacional S.A.
Nov 06, 2025 • Motley Fool SOMEWHAT-BULLISH
Ligand ( LGND ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, Nov. 6, 2025, at 8:30 a.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
Sentiment Snapshot

Average Sentiment Score:

0.135
50 articles with scored sentiment

Overall Sentiment:

Neutral

LGND Reported Earnings

Aug 07, 2025
Jun 30, 2025 (Pre market)
0.17 Surprise
  • Reported EPS: $1.60
  • Estimate: $1.43
  • Whisper:
  • Surprise %: 11.9%
May 08, 2025
Mar 31, 2025 (Pre market)
0.55 Surprise
  • Reported EPS: $1.33
  • Estimate: $0.78
  • Whisper:
  • Surprise %: 70.5%
Feb 27, 2025
Dec 31, 2024 (Pre market)
0.08 Surprise
  • Reported EPS: $1.27
  • Estimate: $1.19
  • Whisper:
  • Surprise %: 6.7%
Nov 07, 2024
Sep 30, 2024 (Pre market)
0.49 Surprise
  • Reported EPS: $1.84
  • Estimate: $1.35
  • Whisper:
  • Surprise %: 36.3%
Aug 06, 2024
Jun 30, 2024 (Post market)
0.34 Surprise
  • Reported EPS: $1.40
  • Estimate: $1.06
  • Whisper:
  • Surprise %: 32.1%
May 07, 2024
Mar 31, 2024 (Post market)
0.42 Surprise
  • Reported EPS: $1.20
  • Estimate: $0.78
  • Whisper:
  • Surprise %: 53.9%
Feb 27, 2024
Dec 31, 2023 (Pre market)
0.72 Surprise
  • Reported EPS: $1.38
  • Estimate: $0.66
  • Whisper:
  • Surprise %: 109.1%
Nov 08, 2023
Sep 30, 2023 (Post market)
0.41 Surprise
  • Reported EPS: $1.02
  • Estimate: $0.61
  • Whisper:
  • Surprise %: 67.2%
Aug 08, 2023
Jun 30, 2023 (Post market)
0.78 Surprise
  • Reported EPS: $1.42
  • Estimate: $0.64
  • Whisper:
  • Surprise %: 121.9%

Financials